Clinical Scorecard: Rapid Hepatitis C Virus RNA Testing at the Point of Care Achieves 15-Minute Results
At a Glance
Category
Detail
Condition
Hepatitis C Virus (HCV) infection
Key Mechanisms
Qualitative detection of HCV RNA via rapid point-of-care PCR testing from capillary whole blood
Target Population
People affected by or at risk of HCV infection, including those accessing harm reduction services, drug treatment clinics, prisons, and mobile outreach
Care Setting
Decentralized and resource-limited settings, primary care, harm reduction services, outreach programs
Key Highlights
Conventional HCV diagnosis requires multiple visits and laboratory-based RNA testing, causing delays and loss to follow-up.
The DASH® Rapid PCR Platform provides a qualitative HCV RNA result in 15 minutes using capillary whole blood, facilitating same-day diagnosis and treatment.
The DASH® assay demonstrates high analytical specificity and sensitivity across HCV genotypes 1–6 with a limit of detection of 200 IU/mL.
Guideline-Based Recommendations
Diagnosis
Integrate point-of-care HCV RNA testing to reduce time to diagnosis and improve linkage to care.
Use capillary whole blood samples for rapid testing to enhance acceptability and feasibility in decentralized settings.
Management
Implement test-and-treat strategies enabled by rapid RNA results to increase treatment uptake and reduce loss to follow-up.
Monitoring & Follow-up
Further large-scale prospective studies are needed to validate real-world performance of rapid point-of-care HCV RNA assays.
Risks
Be aware of technical challenges in nucleic acid extraction from whole blood that may affect test accuracy.
Consider cost, portability, and usability factors when deploying point-of-care RNA tests in various settings.
Patient & Prescribing Data
Individuals at risk of or living with HCV infection requiring rapid diagnosis and treatment initiation
Rapid RNA testing reduces time to treatment and increases treatment uptake by enabling same-visit diagnosis and care linkage.
Clinical Best Practices
Utilize rapid HCV RNA point-of-care tests to minimize patient loss to follow-up and improve treatment initiation rates.
Deploy testing platforms with short turnaround times (under 20 minutes) to enhance patient acceptability and clinical workflow.
Ensure testing platforms meet regulatory approvals (e.g., FDA 510(k) clearance) and usability standards for decentralized care.
Conduct ongoing evaluation of test performance, operator preferences, and feasibility in diverse clinical settings.
